The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

The FDA sent out "100 cease-and-desist letters" to brands in response to what it says is "deceptive" pharma advertising - which could massively impact pharma's $7 billion U.S. national TV ad ...

In response to what it says is "deceptive" pharmaceutical ads, the FDA sent out "100 cease-and-desist letters" to brands - a move that could have massive impact on pharma's $7 billion U.S. national TV ...

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...

Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...

The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9,000 positions to streamline ...

Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...

After struggling to find relief, GLP-1s were the "miracle solution" to their PCOS symptoms. But without insurance coverage, ...

Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular ...

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed ...

Benefits consultants Aon and WTW told the Wall Street Journal that employer health-coverage costs are set to surge about 9.5% ...